April 23-25, 2019

Day One

Day Two
Thursday, 25TH APRIL 2019

Coffee & Networking

Chair’s Opening Remarks

Driving the Prioritsation & Characterisation of Neoantigens

One for All & All for One – Bioengineering of T cells with Specificity for Neoantigens in Solid Tumours


  • Targeting of solid tumours based on the identification and prioritisation of neoantigens
  • Targeting of neoantigens based on the identification and prioritisation of T-cell receptors (TCRs)
  • Using Sleeping Beauty system to express neoantigen-specific TCRs in clinical grade T cells

Integrating Non-Mutated and Neoantigens into Highly Personalised Immunotherapy Approaches – Clinical Experiences

  • Norbert Hilf Director of Translational Development, Immatics


  • Reviewing the role of neoantigens and non-mutated antigens in tumors with low mutational burden
  • Understand the GAPVAC approach: concept of actively personalized vaccination in newly diagnosed glioblastoma
  • Analysing final results of the GAPVAC-101 study with a focus on biological activity data
  • Assessing challenges for personalized immunotherapies
  • Going beyond GAPVAC: highly personalized Adoptive Cellular Therapy

Beyond Algorithms: The ATLAS Bioassay Method for Neoantigen Identification & Characterization


  • Assessing how HLA agnostic assay identifies CD4 and CD8 T cell neoantigens
  • Analysing the uniquely distinguished mutations that elicit stimulatory and inhibitory T cell responses
  • Novel updates on clinical development of personalised neoantigen vaccine based on ATLAS platform

Morning Refreshments & Networking

Evaluating the Clinical Development of Personalised Cancer Immunotherapy

Bringing Individualised Neoantigen-based Cancer Vaccines into the Clinic; Challenges, Learnings & Victories


  • Overcoming the hurdles of moving into a new field that challenges standard regulatory guidelines
  • How to meet the demands on lead time, COGS and efficacy for individual vaccines
  • How to deal with the rapid evolvement of combination strategies
  • An update on Vaccibody’s VB N-01 study using personalised vaccines in patients with advanced cancer

Next Generation Immunotherapy Targeting the Cancer Stem Cell


  • AIVITA Biomedical has developed a personalized cancer immunotherapy consisting of autologous dendritic cells loaded with autologous tumor antigens from autologous self-renewing tumor-initiating cells
  • Successive manufacturing improvements have rendered the treatment economical and reliable to produce. The treatment is in Phase 2 clinical trials for glioblastoma and ovarian cancer, and AIVITA is also seeking conditional approval to commercialize for melanoma in Japan
  • Mechanism of action analyses have determined tumorigenicity and driver immunogenicity of the isolated tumor-initiating cells, changes in the blood of responsive patients that are consistent with the induction of a Th17 cytotoxic response, as well as surrogate and predictive markers of efficacy
  • Exomic analyses with HLA profiling on multiple patient samples have identified common driver neo-antigens

Lunch & Networking

Panel Discussion: Global Clinical Development of Neoantigen-based Cancer Therapies

Induction of Neoantigen-specific T cells with Self-Assembling Nanoparticles


  • Exploring the properties of peptide-based vaccines that impact CD8 T cell induction
  • Evaluating self-assembling nanoparticles as a modular platform for optimising T cell responses
  • Analysing the effect of vaccine dose, route, and TLR-7/8 agonist potency on T cell induction in mice and primates

Chair’s Closing Remarks

Close of 3rd European NeoAg Summit